Safety study of efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Addiction
This study is completed in France. It is testing efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption for Addiction.
AddictionDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Cyproheptadine may be useful for adults experiencing addiction.
What would participation involve?
Participants may receive Cyproheptadine, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in France.
Who is it mainly for?
This study appears to be mainly for adults with addiction.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: November 30, 2019
Recruitment status
Completed
Enrollment listed in the registry
154
Sponsor
Kinnov Therapeutics
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
France
Age range
From 18 Years to 65 Years
Official registry ID
NCT04108104
Official title
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
France · 35 sites
Centre Hospitalier d'Abbeville
Abbeville
Site status: Not listed — confirm with the team
Centre d'Addictologie "Pierre-Fouquet" - CHD La Candélie
Agen
Site status: Not listed — confirm with the team
clinique de la Bréhonnière
Astillé
Site status: Not listed — confirm with the team
Centre de Soins, d'Accompagnement et de Prévention en addictologie Bizia
Bayonne
Site status: Not listed — confirm with the team
Centre Hospitalier de la Côte Basque - Service d'addictologie
Bayonne
Site status: Not listed — confirm with the team
Cabinet Médical
Bersée
Site status: Not listed — confirm with the team
CHRU Brest - Hôpital Cavale Blanche
Brest
Site status: Not listed — confirm with the team
HIA Clermont Tonnerre
Brest
Site status: Not listed — confirm with the team
Service Universitaire d'Addictologie de Lyon - Centre Hospitalier Le Vinatier
Bron
Site status: Not listed — confirm with the team
Centre Hospitalier Universitaire de Clermont-Ferrand
Clermont-Ferrand
Site status: Not listed — confirm with the team
Centre Hospitalier Intercommunal de Créteil - Service Hépato-Gastro-entérologie
Créteil
Site status: Not listed — confirm with the team
Centre Hospitalier Universitaire de Dijon - Service d'addictologie
Dijon
Site status: Not listed — confirm with the team
Centre Hospitalier Annecy Genevois
Épagny
Site status: Not listed — confirm with the team
Centre Hospitalier Camille Claudel
La Couronne
Site status: Not listed — confirm with the team
Centre Hospitalier de La Rochelle
La Rochelle
Site status: Not listed — confirm with the team
Centre Hospitalier Emile-Roux
Le Puy-en-Velay
Site status: Not listed — confirm with the team
Centre hospitalier Esquirol - Pôle d'addictologie en Limousin
Limoges
Site status: Not listed — confirm with the team
Centre Hospitalier Universitaire de Lyon - Hôpital de la Croix Rousse
Lyon
Site status: Not listed — confirm with the team
CHU Provences-Alpes Côte d'Azur Hôpital Publique
Marseille
Site status: Not listed — confirm with the team
Clinique Saint Barnabé
Marseille
Site status: Not listed — confirm with the team
Centre Hospitalier Régional Universitaire Saint Eloi - Service d'addictologie et complications somatiques
Montpellier
Site status: Not listed — confirm with the team
Hôpital St-Julien
Nancy
Site status: Not listed — confirm with the team
Centre Hospitalier Universitaire de Nantes - site Hôtel-Dieu
Nantes
Site status: Not listed — confirm with the team
Centre Hospitalier universitaire de Nice - Hôpital Archet II
Nice
Site status: Not listed — confirm with the team
Hôpital Universitaire Carémeau
Nîmes
Site status: Not listed — confirm with the team
Centre Hospitalier Régional d'Orléans - Hôpital La Source - Service d'hépato-gastro-entérologie et oncologie digestive
Orléans
Site status: Not listed — confirm with the team
Centre Médico-Psychologique Saint-Marc
Orléans
Site status: Not listed — confirm with the team
Centre Hospitalier Sainte-Anne
Paris
Site status: Not listed — confirm with the team
Hôpital Fernand-Widal
Paris
Site status: Not listed — confirm with the team
Centre Hospitalier de Pau - Unité d'addictologie
Pau
Site status: Not listed — confirm with the team
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou - Centre hépato-digestif
Rennes
Site status: Not listed — confirm with the team
Centre Ambulatoire de Santé Mentale
Saint-Martin-d'Hères
Site status: Not listed — confirm with the team
Centre Hospitalier de Saint-Nazaire
Saint-Nazaire
Site status: Not listed — confirm with the team
Association Hospitalière de Bourgogne Franche-Comté
Saint-Rémy
Site status: Not listed — confirm with the team
cabinet médical du Dr El-Ayoubi
Tours
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04108104. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with addiction. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Cyproheptadine, Alpress LP. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Are there criteria about substance use or wanting to reduce it?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Kinnov Therapeutics, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
